Search
Arformoterol
go.drugbank.com/drugs/DB01274ApprovedThe use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients … using long-acting beta agonists for the treatment of asthma.
Karaya gum
go.drugbank.com/drugs/DB10535ApprovedKaraya gum allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingNomegestrol
go.drugbank.com/drugs/DB11636ApprovedNomegestrol is an ingredient in the EMA-authorised product Zoely.
Categories: Sex Hormones and Modulators of the Genital SystemMethscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Metergoline
go.drugbank.com/drugs/DB13520Approved[A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182
Categories: Heterocyclic Compounds with 4 or More RingsNomacopan
go.drugbank.com/drugs/DB14991InvestigationalNomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Categories: Recombinant Protein Inhibitor of Complement Factor 5Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalThe development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. … The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic
Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet)Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5. … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.
Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLEHalothane
go.drugbank.com/drugs/DB01159ApprovedVet approvedWithdrawnA nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly.
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigational[A232955] Other types of enzyme replacement therapy for the treatment of Pompe disease include [alglucosidase alfa] and [avalglucosidase alfa]. … ,[L45275] and the EMA fully approved the drug on March 27, 2023.
Synonyms: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate